539. GS-CA2: A Novel, Potent, and Selective First-In-class Inhibitor of HIV-1 Capsid Function Displays Nonclinical Pharmacokinetics Supporting Long-Acting Potential in Humans |
|
6- |
|
6-(Het)aryl-7-deazapurine ribonucleosides as novel potent cytostatic agents |
|
Abyssomicin 2 reactivates latent HIV-1 by a PKC- and HDAC-independent mechanism |
|
Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a Model. |
|
Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases |
|
The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. |
|
Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile |
|
Blood biomarkers of expressed and inducible HIV-1. |
|
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. |
|
Broad-spectrum Investigational Agent GS-5734 for the Treatment of Ebola, MERS Coronavirus and Other Pathogenic Viral Infections with High Outbreak Potential. |
|
Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. |
|
Characterization of Ebola Virus Disease (EVD) in Rhesus Monkeys for Development of EVD Therapeutics |
|
Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. |
|
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 |
|
Clinical targeting of HIV capsid protein with a long-acting small molecule |
|
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV |
|
Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat |
|
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease |
|
Current status and challenges of antiretroviral research and therapy |
|
Current status and prospects of HIV treatment |
|
Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131. |
|
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses |
|
Drug resistance assessment following administration of RSV fusion inhibitor presatovir to participants experimentally infected with respiratory syncytial virus |
|
Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir. |
|
GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses |
|
GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process |
|
GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model system. |
|
GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma |
|
Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing |
|
Human respiratory syncytial virus memphis 37 causes acute respiratory disease in perinatal lamb lung |
|
Identification of NK Cell Subpopulations That Differentiate HIV-Infected Subject Cohorts with Diverse Levels of Virus Control |
|
In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells |
|
Inhibition of the human organic anion transporter 1 by the caffeine metabolite 1-methylxanthine |
|
Mechanism of active renal tubular efflux of tenofovir |
|
Metabolism and antiretroviral activity of tenofovir alafenamide in CD4+ T-cells and macrophages from demographically diverse donors |
|
Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. |
|
Multiple classes of antiviral agents exhibit in vitro activity against human rhinovirus type C |
|
Mutations in adenosine deaminase-like (ADAL) protein confer resistance to the antiproliferative agents N6-cyclopropyl-PMEDAP and GS-9219. |
|
A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19 |
|
Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells |
|
A novel and efficient one-pot synthesis of symmetrical diamide (bis-amidate) prodrugs of acyclic nucleoside phosphonates and evaluation of their biological activities |
|
Novel targets for HIV therapy |
|
Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. |
|
A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome. |
|
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection |
|
Quantitative microscopy of functional HIV post-entry complexes reveals association of replication with the viral capsid |
|
Rapid In Vitro Evaluation of Antiretroviral Barrier to Resistance at Therapeutic Drug Levels |
|
Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge |
|
Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice |
|
Role of cathepsin A and lysosomes in the intracellular activation of novel antipapillomavirus agent GS-9191. |
|
Search for small molecule activators of latent HIV. |
|
Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue |
|
Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms |
|
Study of marine natural products including resorcyclic acid lactones from Humicola fuscoatra that reactivate latent HIV-1 expression in an in vitro model of central memory CD4+ T cells |
|
Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring |
|
Synthesis and significant cytostatic activity of 7-hetaryl-7-deazaadenosines |
|
Synthesis, anti-HIV activity, and resistance profiles of ribose modified nucleoside phosphonates |
|
Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents |
|
Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells |
|
Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity |
|
Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures |
|
Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. |
|
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys |
|
TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells |
|
TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy. |
|
Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy |
|
Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication |
|
Unlikely association of multidrug-resistance protein 2 single-nucleotide polymorphisms with tenofovir-induced renal adverse events |
|
Visualizing the molecular interactions of a nucleotide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex |
|